Profil
Tom Newman has a current job as the President of OrthoStim.
Postes actifs de Tom Newman
| Sociétés | Poste | Début |
|---|---|---|
OrthoStim
 OrthoStim Electronic Equipment/InstrumentsElectronic Technology OrthoStim, a company under Leonhardt Ventures LLC, offers a technology platform that utilizes bioelectric stimulation and stem cell-based compositions to promote the body's own healing potential. OrthoStim is based in Irvine, CA, and is led by CEO Howard J. Leonhardt. The company aims to regenerate joints and eliminate joint arthritis pain through bioelectric stimulations and protein expressions for inflammation management, healing, pain relief, and regeneration promotion. OrthoStim's technology platform includes patented customized inflammation management and a proprietary biologics mix that includes bioelectric pre-treated PRF, secretome from amniotic sourcing, selected exosomes, and patent-pending klotho expressing MSCs. The company targets knee, hip, elbow, tendon, cartilage, bone, and muscle indications. However, the products described on the company's website are still in early stage development and are not yet proven safe or effective in statistically significant controlled clinical studies. | President | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
OrthoStim
OrthoStim Electronic Equipment/InstrumentsElectronic Technology OrthoStim, a company under Leonhardt Ventures LLC, offers a technology platform that utilizes bioelectric stimulation and stem cell-based compositions to promote the body's own healing potential. OrthoStim is based in Irvine, CA, and is led by CEO Howard J. Leonhardt. The company aims to regenerate joints and eliminate joint arthritis pain through bioelectric stimulations and protein expressions for inflammation management, healing, pain relief, and regeneration promotion. OrthoStim's technology platform includes patented customized inflammation management and a proprietary biologics mix that includes bioelectric pre-treated PRF, secretome from amniotic sourcing, selected exosomes, and patent-pending klotho expressing MSCs. The company targets knee, hip, elbow, tendon, cartilage, bone, and muscle indications. However, the products described on the company's website are still in early stage development and are not yet proven safe or effective in statistically significant controlled clinical studies. | Electronic Technology |
